Clinical trial
Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled…
NCT00483743 · Syntara, Industry · Completed
Key facts
| NCT number | NCT00483743 |
|---|---|
| Title | Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients |
| Official title | Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled, 6-week Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI 1020 in COPD Patients. |
| Lead sponsor | Syntara, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Copd Bronchitis |
| Intervention type | Drug |
| Interventions | TPI 1020, Budesonide, Placebo |
| Enrollment | 62 |
| Start date | Nov 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jun 7, 2007 |
| Last update posted | Dec 3, 2012 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: